EKF vs. CREO, NCYT, NIOX, MXCT, ANCR, AGY, 4BB, FUM, KOO, and BXP
Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include Creo Medical Group (CREO), Novacyt (NCYT), NIOX Group (NIOX), MaxCyte (MXCT), Animalcare Group (ANCR), Allergy Therapeutics (AGY), 4basebio (4BB), Futura Medical (FUM), Kooth (KOO), and Beximco Pharmaceuticals (BXP). These companies are all part of the "medical" sector.
EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
EKF Diagnostics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
71.4% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 43.0% of Creo Medical Group shares are owned by institutional investors. 5.1% of EKF Diagnostics shares are owned by insiders. Comparatively, 20.7% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, EKF Diagnostics and EKF Diagnostics both had 3 articles in the media. Creo Medical Group's average media sentiment score of 0.47 beat EKF Diagnostics' score of 0.30 indicating that Creo Medical Group is being referred to more favorably in the news media.
EKF Diagnostics has a net margin of 4.47% compared to Creo Medical Group's net margin of -85.54%. EKF Diagnostics' return on equity of 3.83% beat Creo Medical Group's return on equity.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.
Summary
EKF Diagnostics beats Creo Medical Group on 10 of the 14 factors compared between the two stocks.
Get EKF Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EKF Diagnostics Competitors List
Related Companies and Tools
